gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development

Modeling and simulation (M&S) is increasingly used in drug development to characterize pharmacokinetic-pharmacodynamic (PKPD) relationships and support various efforts such as target feasibility assessment, molecule selection, human PK projection, and preclinical and clinical dose and schedule determination. While model development typically require mathematical modeling expertise, model exploration and simulations could in many cases be performed by scientists in various disciplines to support the design, analysis and interpretation of experimental studies. To this end, we have developed a versatile graphical user interface (GUI) application to enable easy use of any model constructed in SimBiology® to execute various common PKPD analyses. The MATLAB®-based GUI application, called gPKPDSim, has a single screen interface and provides functionalities including simulation, data fitting (parameter estimation), population simulation (exploring the impact of parameter variability on the outputs of interest), and non-compartmental PK analysis. Further, gPKPDSim is a user-friendly tool with capabilities including interactive visualization, exporting of results and generation of presentation-ready figures. gPKPDSim was designed primarily for use in preclinical and translational drug development, although broader applications exist. gPKPDSim is a MATLAB®-based open-source application and is publicly available to download from MATLAB® Central™. We illustrate the use and features of gPKPDSim using multiple PKPD models to demonstrate the wide applications of this tool in pharmaceutical sciences. Overall, gPKPDSim provides an integrated, multi-purpose user-friendly GUI application to enable efficient use of PKPD models by scientists from various disciplines, regardless of their modeling expertise.

[1]  Albert Wang,et al.  Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..

[2]  Piet H. Van Der Graaf,et al.  A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation , 2013, Comput. Methods Programs Biomed..

[3]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[4]  W W Offen,et al.  A pharmacokinetic profile of nizatidine in man. , 1987, Scandinavian journal of gastroenterology. Supplement.

[5]  P. Hartvig,et al.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[6]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Shiu-Nan Chen,et al.  Apoptotic cell: linkage of inflammation and wound healing , 2014, Front. Pharmacol..

[8]  R R Almon,et al.  SERUM ACETYLCHOLINE‐RECEPTOR ANTIBODIES IN MYASTHENIA GRAVIS * , 1976, Annals of the New York Academy of Sciences.

[9]  Johan Gabrielsson,et al.  Non-compartmental analysis. , 2012, Methods in molecular biology.

[10]  A. Kamath,et al.  Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. , 2016, Drug discovery today. Technologies.

[11]  William J. Jusko,et al.  Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  A. Krause,et al.  Visualization and Communication of Pharmacometric Models With Berkeley Madonna , 2014, CPT: pharmacometrics & systems pharmacology.

[13]  J Wojciechowski,et al.  Interactive Pharmacometric Applications Using R and the Shiny Package , 2015, CPT: pharmacometrics & systems pharmacology.